Podcasts

Episode 24 | The Changing Course of Outcomes in Early Stage NSCLC: Surgical and Respiratory Medicine Considerations

A/Prof Melissa Moore is joined by Dr Katharine See and Dr Naveed Alam to discuss and review the findings and implications for NSCLC patients.

The Changing Course of Outcomes in Early Stage NSCLC: Surgical and Respiratory Medicine Considerations

Episode Summary

In this Podcast, we discuss early NSCLC management and treatment, particularly in light of how immunotherapy will impact surgical and respiratory medicine as the landscape evolves with new data. A/Prof Melissa Moore is joined by Dr Katharine See and Dr Naveed Alam to discuss and review the findings and implications for NSCLC patients.

 

Thank you to Roche for collaborating on this podcast.

Show Hosts

This episode’s host are:

  • A/Prof Melissa Moore, Educational Chair, TOGA; Medical Oncologist
  • Dr Katharine See, Director and Head of Respiratory Medicine, Northern Hospital, Melbourne
  • Dr Naveed Alam, Thoracic Surgeon, St Vincent’s Hospital and Epworth

 

Play Episode 24 | The Changing Course of Outcomes in Early Stage NSCLC: Surgical and Respiratory Medicine Considerations

More Podcasts

Host A/Prof Mel Moore interviews Dr Jazmin Eckhaus, a practising surgeon in the subspecialty of thoracic surgery.
Host A/Prof Adnan Nagrial leads a panel discussing the clinical implications of the broad PBS listing of ipilimumab and nivolumab in Australia.
Host A/Prof Deme Karikios leads a panel discussion focusing on the recent, groundbreaking broad PBS listing of certain immunotherapy agents in Australia.
Host A/Prof Rachel Roberts-Thomson leads a panel discussion focusing on the landscape of BRAF-mutated non-small cell lung cancer.
In this episode of TOGA's Conversations in Lung Cancer Research, host A/Prof Malinda Itchins, a medical oncologist and clinician researcher at Royal North Shore Hospital
In this episode, we welcome A/Prof Surein Arulananda, the interim Director of Medical Oncology and Thoracic Oncology Trials Lead at Monash Health.